OvaScience Appoints Mary Fisher to Company’s Board of Directors

  OvaScience Appoints Mary Fisher to Company’s Board of Directors

Business Wire

CAMBRIDGE, Mass. -- June 11, 2013

OvaScience^SM, (NASDAQ: OVAS), a life sciences company focused on the
discovery, development and commercialization of new treatments for
infertility, announced today the appointment of Mary Fisher, President and
Chief Executive Officer of Colorescience, to its Board of Directors.

“Mary understands how to commercialize consumer health care products, and we
are fortunate to have her join our Board at a time when we are planning for
the launch of our first product to treat female infertility,” said Michelle
Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. "She also shares our
commitment to educate and advocate for the unmet needs of patients. We look
forward to Mary’s contributions as we work together to bring new treatment
options to the growing number of women who struggle with infertility.”

Ms. Fisher brings more than 25 years of experience in the pharmaceutical and
biotechnology industries. Ms. Fisher currently serves as Chief Executive
Officer and Director at Colorescience, a former division of SkinMedica, Inc.,
where she served as Chief Executive Officer from 2008 until 2012, when she led
the successful sale of the company to Allergan, Inc. for $375 million. Prior
to joining SkinMedica, Ms. Fisher was the Chief Operating Officer of Acorda
Therapeutics, a biotechnology company focused on developing products for the
treatment of central nervous system disorders. There, she helped execute the
company’s restructuring, initial public offering and a $50 million acquisition
that transitioned Acorda from a developmental platform to a commercial stage
operation. Ms. Fisher has served as a Pharmaceutical Consultant for companies
such as Acorda Therapeutics and Roche Diagnostics and specialized in
commercialization strategy, resource and outsource planning, pricing strategy
and tactics, distribution planning, managed care contracting and forecasting.
Previously, she held the role of Vice President, Strategic Healthcare and
Commercial Operations at Cephalon, Inc., and Manager, Communications at
Immunex. She currently serves as a Board Member of the Neuroscience Nursing
Foundation and is a Member of the Women’s Dermatological Society and the
Dermatology Foundation Leader’s Society. Additionally, Ms. Fisher co-founded
Ann Olsen Endowment, a cancer patient advocacy group, in 1987.

“OvaScience’s technology platform has the potential to generate new treatments
– not only for women with infertility, but also for women who have no other
options for preserving their future fertility, including those diagnosed with
cancer,” said Ms. Fisher. “I am pleased to be joining the Board and working
with OvaScience management to help these women start and grow their families.”

About OvaScience

OvaScience (NASDAQ: OVAS) is a life sciences company focused on the discovery,
development and commercialization of new treatments for infertility. The
Company’s patented technology is based on the discovery of egg precursor cells
(EggPC^SM), which are found in the ovaries. By applying proprietary technology
to identify and purify EggPCs, AUGMENT^SM aims to improve egg quality and
increase the success of in vitro fertilization (IVF). OvaScience’s team of
scientists, physicians and advisers includes recognized leaders in the field
of reproductive medicine. For more information, please visit
www.ovascience.com.

Forward-Looking Statements

This press release includes forward-looking statements about the Company’s
strategy, future plans and prospects, including statements regarding the
development and planned launch of the Company’s product candidates, including
AUGMENT. Any statements in this release about our strategy, plans, prospects
and future expectations, financial position and operations, and other
statements containing the words “anticipate,” “believe,” “estimate,” “expect,”
“intend,” “may,” “plan,” “predict,” “project,” “target,” ”aim,” “potential,”
“will,” “would,” “could,” “should,” “continue,” and similar expressions,
constitute forward-looking statements for the purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of 1995. Actual
results may differ materially from those indicated by these forward-looking
statements as a result of various important factors, including risks related
to: our expectations regarding the regulatory approvals required for AUGMENT;
the science underlying our two product candidates, which is unproven; our
ability to obtain, maintain and protect intellectual property utilized by our
products; our ability to obtain additional funding to support our activities;
our dependence on third parties; the successful development of, and ability to
obtain regulatory approval for, our product candidates; our ability to
commercialize our product candidates, including AUGMENT, on the timeline we
expect, if at all; competition from others; and our short operating history;
as well as those risks more fully discussed in the “Risk Factors” section of
our most recently filed Quarterly Report on Form 10-Q or Annual Report on Form
10-K. The forward-looking statements contained in this press release reflect
our current views with respect to future events. We anticipate that subsequent
events and developments will cause our views to change. However, while we may
elect to update these forward-looking statements in the future, we
specifically disclaim any obligation to do so. These forward-looking
statements should not be relied upon as representing our view as of any date
subsequent to the date hereof.

Contact:

OvaScience, Inc.
Theresa McNeely, 617-299-7356
EVP, Strategic Corporate Communications
tmcneely@ovascience.com